Randomized, double ‐blind, placebo‐controlled 8‐week trial of the efficacy, safety, and tolerability of 5, 10, and 20 mg/day vortioxetine in adults with major depressive disorder

ConclusionWhile vortioxetine failed to meet significance versus placebo in the primary efficacy analysis, there was evidence of efficacy for the 10‐ and 20‐mg doses in secondary analyses. Vortioxetine was safe and well tolerated. Additional studies appear warranted.

Source: Psychiatry and Clinical Neurosciences - October 3, 2017 Category: Neuroscience Authors: Akira Nishimura, Yutaka Aritomi, Kiyofumi Sasai, Tadayuki Kitagawa, Atul R. Mahableshwarkar Tags: Regular Article Source Type: research